Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2024Etats-Unis de son expansion commerciale aux Etats-Unis,.

Event

Dates*

2023 Full-Year Revenue

January 15, 2024

2023 Full-Year Results

March 5, 2024

2024 First-Quarter Revenue

April 9, 2024

Annual General Meeting

April 25, 2024

2024 First-Half Revenue

July 9, 2024

2024 First-Half Results

September 10, 2024

2024 Third-Quarter Revenue

October 8, 2024

(*) Subject to change. Press releases will be issued after market close.

Upcoming financial publication

  • 2023 Full-Year Revenue, on January 15, 2024 after market

About IMPLANET Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributing medical technology equipment. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered into a commercial, technological and financial partnership with SANYOU MEDICAL, China's second largest medical device manufacturer. IMPLANET employs 43 staff and recorded a consolidated revenue of €8.0 million in 2022. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.Implanet.com.

IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO Tél. : +33 (0)5 57 99 55 55 investors@Implanet.com

NewCap Investor Relations Mathilde Bohin Nicolas Fossiez Tél.: +33 (0)1 44 71 94 94 Implanet@newcap.eu

NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44 71 94 94 Implanet@newcap.eu

Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Implanet
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Implanet